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Osteoarthritis (OA) is increasingly prevalent as the popu-
lation ages, and current treatments focus on the relatively 
short-term relief of symptoms. Clinical trials of disease 
modiﬁ  cation are expensive, requiring prolonged follow-
up of large numbers of participants. In the current global 
ﬁ  nancial climate, there is renewed interest in the OA-
modifying potential of existing treatments that have been 
developed for other indications. Bisphosphonates repre-
sent one such class of agent, and the paper by Moreau 
and colleagues [1] in a recent issue of Arthritis Research 
& Th  erapy provided useful insights into the potential of 
this class for OA.
Moreau and colleagues reported reduced pain responses 
when subcutaneous tiludronate was administered to dogs 
after surgical induction of OA. Furthermore, tiludronate 
reduced synovitis (eﬀ  usion, synovial ﬂ  uid prostaglandin 
E2 concentration, and lining cell score) and increased 
subchondral bone thickness. By contrast, an earlier 
clinical trial of risedronate in patients with OA revealed a 
disappointing lack of symptom relief compared with 
placebo [2]. However, lack of eﬃ   cacy may be explained 
by the limited potency of risedronate or, in this 
hetero  genous disease that varies with time, inadequate 
targeting to those most likely to beneﬁ  t.  Collectively, 
these reports raise some important questions about the 
use of bisphosphonates and general issues for the 
development of new treatments in OA. How clinically 
relevant are animal models? Which key pathogenic 
mechanisms are amenable to intervention? How can 
treatments be targeted to those mechanisms in the right 
people at the right time?
Surgical models build on the well-recognized asso  cia-
tion between OA and preceding internal derangement 
[3]. Th  eir predictable onset and rapid development by 
comparison with spontaneous models facilitate the 
testing of pharmacological interventions. Most resear-
chers use small-rodent models of OA, although it has 
been argued that these may inadequately represent the 
pathogenic processes in humans because of diﬀ  erences in 
aging and joint biomechanics. Moreau and colleagues 
partially avoided these problems by studying OA in dogs, 
although this raises its own ethical issues. Th  e authors 
maximized the scientiﬁ   c outputs from their study by 
reporting multiple clinical, biochemical, and histological 
outcomes. Th   ey minimized animal numbers by referring 
to historical controls rather than using sham surgery. 
Th  is does, however, hinder interpretation of whether 
anti-inﬂ  ammatory  eﬀ   ects are directed at OA itself or 
post-surgical inﬂ  ammation.
Bisphosphonates could act through several mecha-
nisms. Abnormal bone turnover in OA leads to a zone of 
osteoporosis beneath the thickened subchondral plate, 
altered ﬂ  exibility, and increased microfracture [4]. Osteo-
clasts mediate the extension of channels from marrow 
spaces into the non-calciﬁ   ed articular cartilage. Th  e 
resulting loss of osteochondral integrity exposes sub-
chondral nerves to proinﬂ  ammatory and algesic factors 
from the synovial ﬂ  uid and permits sensory nerve growth 
into the non-calciﬁ  ed articular cartilage [5]. Furthermore, 
osteoclasts may reduce pH at the osteochondral junction, 
thereby sensitizing and activating sensory nerves through 
actions on ion channels on their peripheral terminals [6].
Th   e data of Moreau and colleagues are consistent with 
eﬀ  ects of bisphosphonates on subchondral bone turnover 
but also suggest possible actions on synovitis. Inﬂ  am  ma-
tion is a common feature of OA and is associated both 
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Synovitis and subchondral bone turnover are 
associated with pain in osteoarthritis. Bisphosphonates 
provide tools for investigating these pathogenic 
mechanisms and also may have therapeutic potential. 
Translating preclinical fi  ndings into new treatments 
for human osteoarthritis requires a critical appraisal 
and refi  nement of animal models, identifi  cation of 
those pathogenic mechanisms that are amenable to 
intervention, and pharmacological targeting of those 
mechanisms in the right people at the right time.
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Inﬂ   am  mation in OA synovium is characterized by a 
predominance of macrophages, which can be targeted by 
bisphosphonates [8]. However, anti-inﬂ  ammatory cyclo-
oxygenase inhibitors and glucocorticosteroids have only 
short-term eﬀ   ects on pain in humans. Th  is may be 
because the catabolic eﬀ   ects of these inhibitors and 
gluco corticosteroids  oﬀ   set potential long-term clinical 
beneﬁ   t, and the possibility that bisphosphonates may 
protect joint structure while inhibiting inﬂ  ammation 
deserves further study.
Th   e quest for structural disease modiﬁ  cation in OA has 
focused largely on joint space narrowing, indicative of 
cartilage loss and meniscal extrusion, and osteophytosis. 
However, each of these deﬁ  nes structures that may not be 
direct sources of pain. Th   e data of Moreau and colleagues 
support the ﬁ   ndings of other groups indicating that 
structural treatments, despite having little eﬀ  ect  on 
chondropathy or osteophytosis, could reduce pain [9]. 
Magnetic resonance imaging features more closely asso-
ciated with pain in OA include synovitis and bone 
marrow lesions.
Bone marrow lesions identify regions of increased 
subchondral bone turnover and therefore may provide a 
biomarker that can predict response to bisphosphonates. 
Laslett and colleagues [10] recently reported a placebo-
controlled trial of the potent parenteral bisphosphonate, 
zoledronic acid, and showed improved pain in people 
with OA and bone marrow lesions. It remains to be 
determined, however, whether bisphosphonates act exclu-
sively through subchondral bone turnover or whether 
they may also be eﬀ  ective if targeted to people during 
OA-associated synovitis.
Animal models reﬂ  ect the understanding of the patho-
genesis of OA at the time they were developed. Investi-
gating subchondral bone changes and synovitis requires a 
critical use and reﬁ   nement of these models. A better 
understanding of how they reﬂ  ect the clinical spectrum 
of OA will facilitate the translation of novel treatments to 
clinical practice. Th   e bisphosphonate story continues to 
evolve and there remains optimism that it may lead to 
targeted treatments with greater eﬀ  ectiveness in the near 
future.
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